Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR2 | O15552 | 11/20 | 0.59 |
| ▸ | CNR2 | P34972 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.35 |
| ▸ | RAB9A | P51151 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | UCHL1 | P09936 | 3/20 | 0.33 |
| ▸ | USP30 | Q70CQ3 | 3/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1916352 | 1.00 | FFAR2 (0.59) | FFAR2CNR2NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL1914752 | 0.98 | FFAR2 (0.60) | FFAR2CNR2NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL1914746 | 0.98 | FFAR2 (0.60) | FFAR2CNR2NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL2400149 | 0.93 | FFAR2 (0.53) | FFAR2CNR2NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL1916392 | 0.93 | FFAR2 (0.53) | FFAR2CNR2NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL1916122 | 0.92 | FFAR2 (0.56) | FFAR2CNR2NPC1RAB9AUCHL1 | |
| SCHEMBL2402732 | 0.92 | FFAR2 (0.56) | FFAR2CNR2NPC1RAB9AUCHL1 | |
| SCHEMBL2402545 | 0.91 | FFAR2 (0.53) | FFAR2CNR2NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL1915883 | 0.91 | FFAR2 (0.53) | FFAR2CNR2NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL1916346 | 0.90 | FFAR2 (0.56) | FFAR2CNR2NPC1RAB9AUCHL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110230477-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN TREATING METABOLIC DISORDERS | EUROSCREEN S.A. (BE) | 2011-09-22 | — | — | US | claimed |
| WO-2011076734-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN TREATING INFLAMMATORY DISEASES | EUROSCREEN S.A. (BE) | 2011-06-30 | — | — | WO | claimed |
| WO-2011076732-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN TREATING GASTROINTESTINAL DISORDERS | EUROSCREEN S.A. (BE) | 2011-06-30 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110230477-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN TREATING METABOLIC DISORDERS | CPT1A, LIPC, PC | FFAR2 295/4885CNR2 822/4885NPC1 28/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.